Evidence method
Level · gp.fundamentals.capex_revenue_ratio
0.51% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
LCTX · Jun 30, 2025
Lineage Cell Therapeutics, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0000950170-25-107333General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-200.33% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
96.38% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.operating_margin
-715.37% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
112.33% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
44.77% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History16 statesHistory building
Sep 30, 20220/5 normalizedLevel 3Dec 31, 20220/6 normalizedLevel 3Mar 31, 20230/6 normalizedLevel 3Jun 30, 20230/6 normalizedLevel 3Sep 30, 20230/7 normalizedLevel 3Dec 31, 20230/7 normalizedLevel 3Mar 31, 20240/6 normalizedLevel 3Jun 30, 20240/6 normalizedLevel 3Sep 30, 20244/6 normalizedLevel 3Dec 31, 20245/6 normalizedLevel 3Mar 31, 20255/6 normalizedLevel 3Jun 30, 20255/6 normalizedLevel 3Sep 30, 20256/6 normalizedLevel 3Dec 31, 20256/6 normalizedLevel 3Mar 31, 20266/6 normalizedLevel 3Jun 30, 20266/6 normalizedLevel 3
Period transition
What moved in the state?
- Previous
- 6.46%
- Current
- 0.51%
- Delta
- -5.95%
- Previous
- -325.30%
- Current
- -200.33%
- Delta
- 124.97%
- Previous
- 4.02%
- Current
- 96.38%
- Delta
- 92.36%
- Previous
- -433.09%
- Current
- -715.37%
- Delta
- -282.28%
- Previous
- 207.32%
- Current
- 112.33%
- Delta
- -94.99%
- Previous
- 81.03%
- Current
- 44.77%
- Delta
- -36.25%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · LCTX Fundamental State →Transitioned To · LCTX Fundamental State →Transitioned To · LCTX CAPEX_INTENSITY_DECREASED →Transitioned To · LCTX CASH_GENERATION_INCREASED →Transitioned To · LCTX GROWTH_INCREASED →Transitioned To · LCTX PROFITABILITY_DECREASED →Transitioned To · LCTX R_AND_D_INTENSITY_DECREASED →Transitioned To · LCTX SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.